Eurobench.com

voda 3 mei 2024 17:56

0

0,787
3-mei-2024 17:35:26
Verschil
-0,051 (-6,09%)
Dagrange 0,786 - 0,839
Volume
304.028
Gem. (3M) 185,9K

voda 3 mei 2024 17:59

0

Slotkoers 31 dec. 2023 0,713

Slotkoers 05 jan. 2024 0,6715 -0,0415 = -5.82%
Slotkoers 12 jan. 2024 0,653 -0,0185 = -2.76%
Slotkoers 19 jan. 2024 0,606 -0,047 = -7.20%
Slotkoers 26 jan. 2024 0,555 -0,051 = -8.42%
Slotkoers 02 feb. 2024 0,608 +0,053 = +9.55%
Slotkoers 09 feb. 2024 0,576 -0,032 = -5.26%
Slotkoers 16 feb. 2024 0,5615 -0,0145 = -2.52%
Slotkoers 23 feb. 2024 0,564 +0,0025 = +0.45%
Slotkoers 01 mrt. 2024 0,5245 -0,0395 = -7.00%
Slotkoers 08 mrt. 2024 0,506 -0,0185 = -3.53%
Slotkoers 15 mrt. 2024 0,545 +0,039 = +7.71%
Slotkoers 22 mrt. 2024 0,521 -0,024 = -4.40%
Slotkoers 28 mrt. 2024 0,517 -0,004 = -0.77%
Slotkoers 05 apr. 2024 0,515 -0,002 = -0.39%
Slotkoers 12 apr. 2024 0,593 +0,078 = +15.15%
Slotkoers 19 apr. 2024 0,830 +0,237 = +39.97% Wauw, wat een super week zeg!!
Slotkoers 26 apr. 2024 0,819 -0,011 = -1.33%
Slotkoers 03 mei 2024 0,787 -0,032 = -3.91%

Jaarrendement t.o.v. van 31 december 2023 +0,074 = +10.38%

Maandrendementen: (t.o.v. slot vorige maand)

Slotkoers 31 jan. 2024 0,6185 -0,0945 = -13.25%
Slotkoers 29 feb. 2024 0,515 -0,1035 = -16.73%
Slotkoers 28 mrt. 2024 0,517 +0,002 = +0.39%
Slotkoers 30 apr. 2024 0,831 +0,314 = +60.74% !!!!!
Slotkoers 03 mei 2024 0,787 -0,044 = -5.29%

voda 10 mei 2024 17:57

0

Slotkoers 31 dec. 2023 0,713

Slotkoers 05 jan. 2024 0,6715 -0,0415 = -5.82%
Slotkoers 12 jan. 2024 0,653 -0,0185 = -2.76%
Slotkoers 19 jan. 2024 0,606 -0,047 = -7.20%
Slotkoers 26 jan. 2024 0,555 -0,051 = -8.42%
Slotkoers 02 feb. 2024 0,608 +0,053 = +9.55%
Slotkoers 09 feb. 2024 0,576 -0,032 = -5.26%
Slotkoers 16 feb. 2024 0,5615 -0,0145 = -2.52%
Slotkoers 23 feb. 2024 0,564 +0,0025 = +0.45%
Slotkoers 01 mrt. 2024 0,5245 -0,0395 = -7.00%
Slotkoers 08 mrt. 2024 0,506 -0,0185 = -3.53%
Slotkoers 15 mrt. 2024 0,545 +0,039 = +7.71%
Slotkoers 22 mrt. 2024 0,521 -0,024 = -4.40%
Slotkoers 28 mrt. 2024 0,517 -0,004 = -0.77%
Slotkoers 05 apr. 2024 0,515 -0,002 = -0.39%
Slotkoers 12 apr. 2024 0,593 +0,078 = +15.15%
Slotkoers 19 apr. 2024 0,830 +0,237 = +39.97% Wauw, wat een super week zeg!!
Slotkoers 26 apr. 2024 0,819 -0,011 = -1.33%
Slotkoers 03 mei 2024 0,787 -0,032 = -3.91%
Slotkoers 10 mei 2024 0,788 +0,001 = +0.13%

Jaarrendement t.o.v. van 31 december 2023 +0,075 = +10.52%

Maandrendementen: (t.o.v. slot vorige maand)

Slotkoers 31 jan. 2024 0,6185 -0,0945 = -13.25%
Slotkoers 29 feb. 2024 0,515 -0,1035 = -16.73%
Slotkoers 28 mrt. 2024 0,517 +0,002 = +0.39%
Slotkoers 30 apr. 2024 0,831 +0,314 = +60.74% !!!!!
Slotkoers 10 mei 2024 0,788 -0,043 = -5.17%

Eljee66 16 mei 2024 09:35

0

En we gaan weer richting aankoop bedrag , TOP-aandeel

voda 17 mei 2024 17:53

0

0,721
17-mei-2024 17:28:56
Verschil
-0,003 (-0,41%)
Dagrange 0,721 - 0,737
Volume
37.510
Gem. (3M) 194,5K

voda 17 mei 2024 17:56

1

Slotkoers 31 dec. 2023 0,713

Slotkoers 05 jan. 2024 0,6715 -0,0415 = -5.82%
Slotkoers 12 jan. 2024 0,653 -0,0185 = -2.76%
Slotkoers 19 jan. 2024 0,606 -0,047 = -7.20%
Slotkoers 26 jan. 2024 0,555 -0,051 = -8.42%
Slotkoers 02 feb. 2024 0,608 +0,053 = +9.55%
Slotkoers 09 feb. 2024 0,576 -0,032 = -5.26%
Slotkoers 16 feb. 2024 0,5615 -0,0145 = -2.52%
Slotkoers 23 feb. 2024 0,564 +0,0025 = +0.45%
Slotkoers 01 mrt. 2024 0,5245 -0,0395 = -7.00%
Slotkoers 08 mrt. 2024 0,506 -0,0185 = -3.53%
Slotkoers 15 mrt. 2024 0,545 +0,039 = +7.71%
Slotkoers 22 mrt. 2024 0,521 -0,024 = -4.40%
Slotkoers 28 mrt. 2024 0,517 -0,004 = -0.77%
Slotkoers 05 apr. 2024 0,515 -0,002 = -0.39%
Slotkoers 12 apr. 2024 0,593 +0,078 = +15.15%
Slotkoers 19 apr. 2024 0,830 +0,237 = +39.97% Wauw, wat een super week zeg!!
Slotkoers 26 apr. 2024 0,819 -0,011 = -1.33%
Slotkoers 03 mei 2024 0,787 -0,032 = -3.91%
Slotkoers 10 mei 2024 0,788 +0,001 = +0.13%
Slotkoers 17 mei 2024 0,721 -0,067 = -8.50%

Jaarrendement t.o.v. van 31 december 2023 +0,008 = +1.12%

Maandrendementen: (t.o.v. slot vorige maand)

Slotkoers 31 jan. 2024 0,6185 -0,0945 = -13.25%
Slotkoers 29 feb. 2024 0,515 -0,1035 = -16.73%
Slotkoers 28 mrt. 2024 0,517 +0,002 = +0.39%
Slotkoers 30 apr. 2024 0,831 +0,314 = +60.74% !!!!!
Slotkoers 17 mei 2024 0,721 -0,110 = -13.24%

RAMO 22 mei 2024 16:14

1

www.research-tree.com/newsfeed/articl...

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Notice of Results and Annual General Meeting

Paris, France, and Eastleigh and Manchester, UK - 20 May 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it will report its audited financial results for the year ended 31 December 2023 on Thursday, 30 May 2024.

The Company also announces that its Annual General Meeting ("AGM") will be held at 2pm CEST/1pm BST on Wednesday, 26 June 2024 as an open virtual meeting. Further details of the AGM will be provided to shareholders in due course.

Investor webinar

An investor webinar presentation by Lyn Rees, Chief Executive Officer, and Steve Gibson, Chief Financial Officer, relating to the FY 2023 results will take place at 11.00am BST on Thursday, 30 May 2024.

The webinar is open to all existing and potential investors, and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation. Automated French subtitling will be available throughout the presentation.

voda 23 mei 2024 15:04

0

Zal volgens DZR wel weer een shuffle zijn. :-)

€ 0,791
+0,061
(+8,35%)

voda 23 mei 2024 15:45

2

Gaat lekker zo.

€ 0,80
+0,07
(+9,58%)

DeZwarteRidder 23 mei 2024 16:49

0

De aandeelhouders van Novacit zitten te hopen op een uitbraak van de vogeltjesgriep.

voda 23 mei 2024 18:25

0

Toch een mooie dag zo.

0,786
23-mei-2024 17:38:16
Verschil
+0,056 (+7,67%)
Dagrange 0,720 - 0,805
Volume
478.082
Gem. (3M) 193,2K

cruiser2010 23 mei 2024 18:48

0

Misschien dat ze toch nog willen het buiten de rechter te houden 4 juni komt nu wel snel

voda 24 mei 2024 06:53

0

quote:
DeZwarteRidder schreef op 23 mei 2024 16:49:
De aandeelhouders van Novacit zitten te hopen op een uitbraak van de vogeltjesgriep.

Daar hebben ze een paar jaar geleden wel een test voor ontwikkelt.

Schijnt nu toch wel serieus te worden, zie ook deze draad in de koffiekamer.

www.iex.nl/Forum/Topic/1373405/Koffie...

voda 24 mei 2024 17:58

0

0,777
24-mei-2024 17:35:17
Verschil
-0,009 (-1,14%)
Dagrange 0,756 - 0,800
Volume
220.248
Gem. (3M) 200,1K

voda 24 mei 2024 17:59

0

Slotkoers 31 dec. 2023 0,713

Slotkoers 05 jan. 2024 0,6715 -0,0415 = -5.82%
Slotkoers 12 jan. 2024 0,653 -0,0185 = -2.76%
Slotkoers 19 jan. 2024 0,606 -0,047 = -7.20%
Slotkoers 26 jan. 2024 0,555 -0,051 = -8.42%
Slotkoers 02 feb. 2024 0,608 +0,053 = +9.55%
Slotkoers 09 feb. 2024 0,576 -0,032 = -5.26%
Slotkoers 16 feb. 2024 0,5615 -0,0145 = -2.52%
Slotkoers 23 feb. 2024 0,564 +0,0025 = +0.45%
Slotkoers 01 mrt. 2024 0,5245 -0,0395 = -7.00%
Slotkoers 08 mrt. 2024 0,506 -0,0185 = -3.53%
Slotkoers 15 mrt. 2024 0,545 +0,039 = +7.71%
Slotkoers 22 mrt. 2024 0,521 -0,024 = -4.40%
Slotkoers 28 mrt. 2024 0,517 -0,004 = -0.77%
Slotkoers 05 apr. 2024 0,515 -0,002 = -0.39%
Slotkoers 12 apr. 2024 0,593 +0,078 = +15.15%
Slotkoers 19 apr. 2024 0,830 +0,237 = +39.97% Wauw, wat een super week zeg!!
Slotkoers 26 apr. 2024 0,819 -0,011 = -1.33%
Slotkoers 03 mei 2024 0,787 -0,032 = -3.91%
Slotkoers 10 mei 2024 0,788 +0,001 = +0.13%
Slotkoers 17 mei 2024 0,721 -0,067 = -8.50%
Slotkoers 24 mei 2024 0,777 +0,056 = +7.77%

Jaarrendement t.o.v. van 31 december 2023 +0,064 = +8.98%

Maandrendementen: (t.o.v. slot vorige maand)

Slotkoers 31 jan. 2024 0,6185 -0,0945 = -13.25%
Slotkoers 29 feb. 2024 0,515 -0,1035 = -16.73%
Slotkoers 28 mrt. 2024 0,517 +0,002 = +0.39%
Slotkoers 30 apr. 2024 0,831 +0,314 = +60.74% !!!!!
Slotkoers 17 mei 2024 0,777 -0,054 = -6.50%

Louis7 30 mei 2024 09:10

1

30 May NCYT – Full Year 2023 Results (30.05.2024)

novacyt.com/ncyt-full-year-2023-resul...

DeZwarteRidder 30 mei 2024 09:26

0

30 May NCYT – Full Year 2023 Results (30.05.2024)
in Board, News

Novacyt S.A.

(“Novacyt”, the “Company” or the “Group”)

Full Year 2023 results
Integration of Yourgene Health remains on track
Laying the foundations for future growth

Paris, France, and Eastleigh and Manchester, UK – 30 May 2024 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces its audited results for the year ended 31 December 2023. The results include almost four months’ trading of Yourgene Health Limited (formerly plc) (“Yourgene”) following its acquisition by the Group, which completed on 8 September 2023.

Operational Highlights (including post year-end and Yourgene 2023 activities pre-acquisition)

Completed the strategic acquisition of Yourgene, significantly enhancing Novacyt’s global diagnostics business, adding scale and diversification to accelerate long-term growth.
Lyn Rees and John Brown CBE joined the Novacyt Board as Executive and Non-Executive Director respectively.
Lyn Rees appointed Chief Executive Officer following a six-year tenure as CEO of Yourgene Health plc, bringing over 28 years’ global healthcare leadership and commercial experience.
Steve Gibson appointed CFO, and to join the Board along with Dr Jo Mason, CSO, subject to shareholder approval.
IVDR certification: received first IVDR accreditation for the Yourgene DPYD genotyping assay for chemotoxicity in chemotherapy patients; submitted application for Cystic Fibrosis quantitative fluorescence PCR (QF-PCR) test.
Yourgene became a compatible partner of PacBio, a leading global developer of sequencing technology, supporting the use of the LightBench™ instrument (Ranger® Technology) to its global customer base.
Yourgene launched MagBench™ automated DNA extraction platform for NIPT workflows in Asia-Pacific and the Middle East.
Launch of the Primer Design Co-Prep ES instrument, providing automated DNA and RNA extraction using Primer Design assays, for use in multiple applications.
Primer Design launched a range of “complete” assays, including customised mastermix reagent for RUO customers.

Financial Highlights

Acquired the AIM-listed company Yourgene and its subsidiaries for an all-cash consideration of £16.7m on 8 September 2023.
Group statutory revenue for FY2023 was £11.6m, in line with guidance, of which £0.6m relates to COVID-19 (FY2022*: £21.0m, of which £14.7m related to COVID-19).
Group statutory revenue for the non-COVID-19 portfolio of £11.0m represents circa 95% of total revenue (FY2022*: £6.3m).
Group gross profit totalled £3.7m (32%) in FY2023 (FY2022: £5.7m (27%)). This was reduced predominantly as a result of providing for all remaining COVID-19 associated stock, in addition to writing off stock that had not been provided for previously. Excluding the impact of these items, the Group gross profit margin would be in excess of 60%.
Group EBITDA loss in FY2023 totalled £13.7m before exceptional items (FY2022: £13.5m loss).
Loss after tax increased to £28.3m in FY2023 (FY2022: £25.7m loss).
Completed cost savings actions that will deliver over £4.0m of bottom-line improvement, the Group is tracking ahead of schedule on the targeted synergies to be achieved from the Yourgene acquisition.
Cash position at 31 December 2023 was £44.1m (2022: £87.0m), reflecting the cash consideration and associated costs of the acquisition of Yourgene. The Group remains debt free.

*excludes any Yourgene revenue as pre-acquisition

Commenting on the results Lyn Rees, CEO of Novacyt, said: “2023 was a transitional year for Novacyt, during which the Group completed the acquisition of Yourgene, a significant milestone that has enhanced our global diagnostics capabilities, diversified our product portfolio and increased the scale of our non-COVID-19 revenues.

“We continue to focus all efforts towards working as a single business so that the reorganisation of the Group and the resulting synergies will leave us well placed to deliver future growth. We remain focused on driving the global sales of our key clinical and instrumentation products, while also rebuilding our RUO business. The Board believes that investment in R&D combined with our commercial strength is key to achieving long-term growth and we are increasingly well-placed to execute our business strategy.”

DeZwarteRidder 30 mei 2024 09:28

0

Loss after tax increased to £28.3m in FY2023 (FY2022: £25.7m loss).
Completed cost savings actions that will deliver over £4.0m of bottom-line improvement, the Group is tracking ahead of schedule on the targeted synergies to be achieved from the Yourgene acquisition.

Cash position at 31 December 2023 was £44.1m (2022: £87.0m), reflecting the cash consideration and associated costs of the acquisition of Yourgene. The Group remains debt free.

DeZwarteRidder 30 mei 2024 12:54

1

Vileine zegt:

30 mei 2024 12:40
Volgens het forum van Boursorama:
Kortom: Genfit heeft een theoretische waardering van €1 miljard, oftewel een koersdoel van €20.
Verwachte gebeurtenissen: FDA MA (10 juni) + EMA MA (??) + positieve ACLF P2 resultaten die volgende week op het EASL-congres zullen worden gepresenteerd

Pjotr 30 mei 2024 12:59

0

quote:
DeZwarteRidder schreef op 30 mei 2024 12:54:
Vileine zegt:

30 mei 2024 12:40
Volgens het forum van Boursorama:
Kortom: Genfit heeft een theoretische waardering van €1 miljard, oftewel een koersdoel van €20.
Verwachte gebeurtenissen: FDA MA (10 juni) + EMA MA (??) + positieve ACLF P2 resultaten die volgende week op het EASL-congres zullen worden gepresenteerd

verkeerde forum?

Vertraagd	30 mei 2024 15:01
Koers	0,692
Verschil	-0,070 (-9,19%)
Hoog	0,762
Laag	0,640
Volume	776.148
Volume gemiddeld	197.949
Volume gisteren	78.974

Novacyt « Terug naar discussie overzicht

Novacyt de volgende biotech raket!

Meedoen aan de discussie?

Direct naar Forum

Detail

Novacyt nieuws